# Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

> **NCT04419402** · PHASE2 · UNKNOWN · sponsor: **Australian and New Zealand Urogenital and Prostate Cancer Trials Group** · enrollment: 162 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Lu-PSMA
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04419402
- **Lead sponsor:** Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-17
- **Primary completion:** 2024-07-31
- **Final completion:** 2025-01-01
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419402, "Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04419402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*